Boston Scientific is trading 5.7% down at $43.45 after reporting a Q2 2026 earnings beat but issuing more cautious forward guidance.
- Management guided to slower Q3 organic growth and narrowed full-year EPS targets, signaling margin pressure and restructuring headwinds.
- While net sales and adjusted EPS topped expectations, investors are focusing on the tempered outlook despite a strong healthcare sector backdrop.